Victoria Forward

Victoria Forward is an audit partner in the EY biotechnology practice in Cambridge, MA. Vicki joined EY in 2002 and she provides audit services to various public and private companies ranging in size and stage of maturity.

She specializes in clients in the biotechnology industry and is responsible for addressing accounting and business issues faced by her clients, including revenue recognition, mergers and acquisitions, inventory costing and management, equity compensation arrangements and debt and equity financings. She has significant experience with public companies and SEC filing requirements and also has experience working with companies on initial and secondary public offerings, including IPOs of Blueprint Medicines, Jounce Therapeutics, and Tetraphase Pharmaceuticals. 

Vicki has extensive experience in the biotechnology industry.  Her current and prior biotechnology clients include Eleven Biotherapeutics, Blueprint Medicines Corporation, Camp4 Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Kymera Therapeutics, Millennium Pharmaceuticals, Moderna, Paratek Pharmaceuticals, Syros Pharmaceuticals, Tetraphase Pharmaceuticals, and Vertex Pharmaceuticals.

Vicki is a Certified Public Accountant and is a member of the AICPA. She graduated from Boston College with a Bachelor of Science in Finance and Information Systems and the University of Notre Dame with a Master of Science in Accountancy.